Hualan Genetic to Develop Three Harbour BioMed Antibodies in Return for China Rights
September 11, 2020 at 05:39 AM EDT
Hualan Genetic Engineering agreed to develop three Harbour BioMed novel monoclonal and bispecific antibodies in return for China marketing rights to the candidates. Hualan Genetic, previously a company focused on biosimilars, will be responsible for preclinical and process development. It will also make an $8.75 million upfront payment, plus pay royalties. Harbour BioMed, which is headquartered in the US with R&D facilities in China , will retain the rights to the antibodies in the rest of the world. Both companies will collaborate on clinical developments and drug manufacturing. More details.... Share this with colleagues: // //